10-Q: Viatris Reports Q3 Flat Revenue, Deepening Net Loss Amid Impairments

Viatris reported flat total revenues for Q3 2025 but a significant net loss of $128.2 million, alongside a $2.9 billion goodwill impairment for the nine-month period.

Summary

• Total revenues for the three months ended September 30, 2025, were $3,759.9 million, essentially flat compared to $3,751.2 million in the prior year period.
• Net loss for Q3 2025 was $128.2 million, a significant decline from net earnings of $94.8 million in Q3 2024.
• Diluted loss per share for Q3 2025 was $0.11, compared to diluted earnings per share of $0.08 in Q3 2024.
• For the nine months ended September 30, 2025, total revenues decreased by 5% to $10,596.3 million from $11,211.2 million in the prior year period.
• A substantial non-cash goodwill impairment charge of $2.94 billion was recorded in Q1 2025, impacting North America ($707.0 million), Europe ($1,554.0 million), JANZ ($300.8 million), and Emerging Markets ($375.0 million).
• The Indore manufacturing facility received an FDA warning letter and import alert in 2024, negatively impacting Q3 2025 revenues by approximately $100 million and year-to-date revenues by approximately $400 million.
• Research and Development (R&D) expense increased by $52.0 million in Q3 2025 and $89.0 million year-to-date, primarily due to the selatogrel and cenerimod development programs.
• Selling, General and Administrative (SG&A) expense decreased by $116.8 million in Q3 2025 and $294.5 million year-to-date, mainly due to lower acquisition and divestiture-related costs.
• Interest expense decreased by $26.0 million in Q3 2025 and $78.1 million year-to-date, primarily due to 2024 debt repayments.
• Net cash provided by operating activities decreased by $320.1 million to $1,500.1 million for the nine months ended September 30, 2025.
• Net cash used in investing activities was $216.5 million for the nine months ended September 30, 2025, a significant shift from $1,969.4 million provided in the prior year period, largely due to fewer divestiture proceeds.
• The company repurchased approximately 45.6 million shares of common stock for $418.3 million year-to-date under its $2.0 billion share repurchase program.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant net loss, a substantial goodwill impairment charge, declining gross margins, and ongoing operational challenges at the Indore facility. While Q3 revenues were flat and debt was reduced, the overall financial performance for the nine-month period is poor, and extensive legal proceedings add uncertainty. Strategic acquisitions are positive long-term but contribute to immediate R&D expenses.

Positives

• Total revenues for the three months ended September 30, 2025, were essentially flat at $3,759.9 million, showing stability compared to the prior year.
• Net sales in the Greater China segment increased by 10% to $615.2 million in Q3 2025 and 7% to $1,759.6 million year-to-date, driven by strong growth across multiple channels.
• Selling, General and Administrative (SG&A) expenses decreased by $116.8 million in Q3 2025 and $294.5 million year-to-date, reflecting lower acquisition and divestiture-related costs.
• Interest expense decreased by $26.0 million in Q3 2025 and $78.1 million year-to-date, primarily due to 2024 debt repayments.
• The company reached a nationwide settlement framework for opioid-related claims for up to $335 million, with $335 million accrued as of September 30, 2025.
• The company successfully resolved the EpiPen Auto-Injector direct purchaser class action in Kansas with a $73.5 million payment in December 2024, and the Minnesota direct purchaser class action was dismissed.
• The company's share repurchase program has seen approximately $1.00 billion in repurchases through November 5, 2025, demonstrating commitment to shareholder returns.
• The acquisition of Aculys Pharma expands the portfolio of innovative products in Japan, particularly in the CNS therapy area.

Negatives

• Net loss for the three months ended September 30, 2025, was $128.2 million, a significant deterioration from net earnings of $94.8 million in the comparable prior year period.
• Diluted loss per share for Q3 2025 was $0.11, compared to diluted earnings per share of $0.08 in Q3 2024.
• For the nine months ended September 30, 2025, the company reported a net loss of $3,174.8 million, substantially wider than the $117.7 million net loss in the prior year period.
• A non-cash goodwill impairment charge of $2.94 billion was recorded in Q1 2025, reflecting increased business risks and uncertainty.
• Gross profit decreased by $87.7 million in Q3 2025 and $543.0 million year-to-date, with gross margins declining from 39% to 36% in both periods, primarily due to product mix and the Indore Impact.
• The FDA warning letter and import alert for the Indore manufacturing facility negatively impacted Q3 2025 revenues by approximately $100 million and year-to-date revenues by approximately $400 million.
• Other expense (income), net, shifted from an income of $10.2 million in Q3 2024 to an expense of $67.1 million in Q3 2025, largely due to a $100.0 million loss from changes in the fair value of CCPS in Biocon Biologics.
• The income tax provision for Q3 2025 was $120.3 million, a significant change from a $4.3 million benefit in Q3 2024, driven by reduced tax benefits and discrete tax items.
• Net cash provided by operating activities decreased by $320.1 million for the nine months ended September 30, 2025, due to lower operating earnings and timing of cash flows.
• Net cash used in investing activities was $216.5 million for the nine months ended September 30, 2025, a substantial decrease of $2.19 billion compared to cash provided in the prior year, primarily due to fewer proceeds from divestitures.

Risks

• The company experienced a sharp and sustained decline in its share price and significantly increased uncertainty and volatility in geopolitical and economic environments, leading to a $2.94 billion goodwill impairment charge.
• The FDA warning letter and import alert for the Indore manufacturing facility affect 11 actively distributed products in the U.S. and could lead to further supply disruptions and negative impacts in other markets.
• The timing of the FDA reinspection for the Indore facility is uncertain, anticipated in 2026, and there's no guarantee of a favorable outcome.
• Ongoing legal proceedings, including drug pricing, antitrust, securities, opioid, and product liability lawsuits, are complex, difficult to predict, and could result in material losses, damages, fines, and/or civil penalties.
• The company faces risks associated with the timely and successful completion of IPR&D projects, including high costs, uncertainty of clinical trials, and obtaining regulatory approvals for selatogrel and cenerimod.
• Government-imposed price reductions and tender systems in international markets continue to negatively impact sales and gross profit.
• The entrance of additional generic competition, such as for Amitiza 24g in Japan (expected June 2026), can lead to substantial and rapid declines in branded product sales.
• Changes in underlying assumptions for goodwill impairment tests, such as discount rates or terminal growth rates, could necessitate further material impairment charges in future periods, especially for the Greater China reporting unit which had a narrow fair value excess.
• The company is subject to ongoing tax examinations and potential assessments in various jurisdictions, which could result in material losses above current reserves.
• The imposition of tariffs or other trade restrictions on pharmaceutical imports could increase costs, disrupt supply chains, cause manufacturing delays, and reduce profit margins.

Future Outlook

The company anticipates its Indore manufacturing facility will be ready for FDA reinspection in 2026, with no material negative impact expected on Q4 2025 total revenues and earnings from operations from the facility issues. Capital expenditures for the 2025 calendar year are expected to be approximately $300 million to $350 million. The company continues to evaluate potential acquisitions and divestitures as part of its future growth strategy and plans to explore ways to unlock value from its global platform. The termination of a U.S. defined benefit plan is expected to be completed by the end of 2026. The company expects approximately $22.0 million of pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings during the next twelve months.

Management Comments

• The executive management team is focused on ensuring the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders.
• We take very seriously our continued and comprehensive oversight of our entire manufacturing network. Patient safety remains our primary and unwavering focus.
• We will work closely with our customers to mitigate any possible supply disruptions and meet the needs of the patients we serve.

Industry Context

The global pharmaceutical industry is highly competitive and regulated, facing challenges such as rigorous, costly, and unpredictable regulatory approval processes, especially for complex generic products. Generic product revenues are significantly impacted by launch timing and competition, with rapid declines in sales upon generic entry for branded products. Government-imposed price reductions and tender systems in international markets continue to exert downward pressure on sales and profitability. Geopolitical events, inflation, and foreign currency fluctuations also pose ongoing risks to international operations. The company's strategic shift towards innovative assets through acquisitions like Idorsia and Aculys Pharma reflects an industry trend to diversify beyond mature generic portfolios, while ongoing manufacturing and legal challenges highlight the inherent operational and regulatory complexities of the sector.

Comparison to Industry Standards

• The company's gross margins of 36% (Q3 and YTD 2025) and adjusted gross margins of 56% (Q3 and YTD 2025) are lower than the prior year (39% and 58% respectively), indicating pressure on profitability, potentially below industry leaders in branded pharmaceuticals but within range for diversified generic/branded companies facing significant competition and regulatory headwinds.
• The $2.94 billion goodwill impairment charge in Q1 2025, triggered by a sharp decline in share price and increased geopolitical/economic uncertainty, suggests that the company's valuation and future cash flow projections were significantly impacted, potentially more severely than some peers who may have more stable or rapidly growing innovative pipelines.
• The FDA warning letter and import alert for the Indore facility, affecting 11 U.S. products, indicates a significant regulatory compliance issue that can be more impactful for companies with large, globally integrated manufacturing networks compared to those with more localized or less complex supply chains.
• The extensive and costly legal proceedings, including drug pricing, opioid, and product liability litigations, are common across the pharmaceutical industry, but the scale and number of ongoing cases for Viatris suggest a higher-than-average exposure to legal and regulatory risks compared to some specialized or smaller pharmaceutical firms.
• The acquisition of Aculys Pharma, focusing on CNS therapy in Japan, and the Idorsia transaction for selatogrel and cenerimod, align with a broader industry trend of pharmaceutical companies seeking to bolster their innovative, patent-protected portfolios to offset erosion in generic and off-patent branded segments.

Corporate Governance

Legal Proceedings

• EpiPen Auto-Injector Litigation: Resolved a direct purchaser class action in Kansas with a $73.5 million payment in December 2024. Another direct purchaser class action in Minnesota was dismissed. Reached a settlement-in-principle with the State of Indiana. Received a civil subpoena from the Attorney General of the State of Mississippi. Total accrual of approximately $50.0 million for these matters at September 30, 2025.
• Drug Pricing Matters Civil Litigation: Consolidated in an MDL in the Eastern District of Pennsylvania, alleging anticompetitive conduct with respect to generic drugs. Clomipramine bellwether cases (direct and indirect purchaser classes) are stayed pending appeals on class certification. Plaintiffs assert damages of approximately $350 million in each case, subject to trebling or multipliers. Another non-class bellwether trial is scheduled for September 2026.
• Attorneys General Litigation: Multiple states alleging anticompetitive conduct with respect to generic drugs, seeking monetary damages, civil penalties, restitution, and injunctive relief. Motions for summary judgment are pending.
• Securities Related Litigation: Includes the ADIA Litigation (SDNY) alleging false/misleading statements regarding EpiPen, with Mylan's motion for summary judgment pending. The WDPA Mylan N.V. Class Action Litigation regarding manufacturing plants is proceeding to discovery for certain claims. The Skandia Litigation has been resolved and closed. The WDPA Viatris Class Action Litigation regarding projected financial performance and biosimilars was dismissed, and the appeal rejected. Stockholder derivative actions are ongoing. A new putative class action was filed in April 2025 (amended September 2025) regarding regulatory issues at the Indore manufacturing facility.
• Opioids: Defendant in over 1,000 cases. Reached a nationwide settlement framework in April 2025 for up to $335 million over nine years. Accrued approximately $335 million at September 30, 2025. Received civil subpoenas from several State Attorneys General.
• Citalopram: Involved in a U.K. Competition Appeals Tribunal case seeking monetary damages related to EU competition rules violations. Accrued approximately 12.0 million EUR at September 30, 2025.
• Perindopril: Involved in English High Court and Amsterdam District Court cases related to EU competition rules violations. Monetary obligation satisfied in 2014.
• Product Liability: Accrued approximately $67.3 million at September 30, 2025. Includes Nitrosamines litigation (valsartan, ranitidine MDLs, with an agreement in principle to resolve valsartan personal injury lawsuits), Lipitor lawsuits (against Pfizer, assumed by Viatris), and Depo-Provera lawsuits (Viatris dismissed without prejudice from MDL cases, seeking indemnification from Pfizer).
• Intellectual Property: Involved in patent litigation for Yupelri (settlement agreements with several generic companies, one filer remains), Tyrvaya (settlement agreement with generic company), Amitiza in Japan (JPO challenges, appeals, and infringement actions), and Ryzumvi (patent infringement action filed, staying FDA approval until August 3, 2027). Accrued approximately $7.4 million for IP matters at September 30, 2025.

Related Party Transactions

• In connection with the Combination, the company generally assumed liability for, and control of, pending and threatened legal matters relating to the Upjohn Business, including certain matters initiated against Pfizer, and agreed to indemnify Pfizer for liabilities arising out of such assumed legal matters. Pfizer retained certain matters and agreed to indemnify the company for liabilities arising out of such matters.
• The company is seeking indemnification from Pfizer for Depo-Provera claims pursuant to the Separation and Distribution Agreement, and Pfizer is seeking cross-indemnification from the company with respect to the authorized generic product previously sold by Greenstone LLC.

Stakeholder Impact

• Shareholders: Impacted by the significant net loss, goodwill impairment, and declining share price. The share repurchase program aims to return value, and dividends are maintained, but overall financial performance is a concern.
• Patients: The FDA import alert on the Indore facility could lead to supply disruptions for 11 U.S. products, potentially affecting patient access, though exceptions are made for 4 products due to shortage concerns. The acquisition of Aculys Pharma and Idorsia products aims to expand innovative treatment options.
• Employees: The goodwill impairment and ongoing restructuring activities may lead to employee separation costs and impact morale. The Idorsia amendment included additional personnel to expedite program transitions.
• Customers: The Indore facility issues could impact product availability and supply chain reliability, requiring close collaboration to mitigate disruptions.
• Creditors: Debt repayments in 2024 have reduced interest expense, and the company states it is in compliance with debt covenants, but the overall financial performance and large legal accruals could be a concern for credit risk.

Next Steps

• Continue remediation plan at the Indore manufacturing facility, with reinspection anticipated in 2026.
• Evaluate appropriate next steps for the pimecrolimus 0.3% (MR-139) ophthalmic ointment Phase 3 program, which may include revising the planned additional Phase 3 study.
• Oversee the transition of selatogrel and cenerimod development programs to Viatris following the amendment with Idorsia.
• Continue to defend against various ongoing legal proceedings, including drug pricing, opioid, and intellectual property litigations.
• Monitor and evaluate evolving tax legislation, including the Pillar Two Rules, and their potential impact on future tax provisions and financial results.
• Continue to make minimum mandatory contributions to defined benefit pension plans.
• Complete the termination of the U.S. defined benefit plan by the end of 2026.
• Continue to explore potential acquisitions of products and companies, and evaluate potential divestitures of products and businesses as part of future strategy.
• Continue share repurchases under the authorized $2.0 billion program.
• Pay a quarterly cash dividend of $0.12 per share on December 15, 2025.

Key Dates

Recommendation

The company faces significant headwinds, including a substantial net loss driven by a large goodwill impairment, declining gross margins, and ongoing operational issues at its Indore manufacturing facility which have impacted revenues. Extensive legal proceedings, particularly in drug pricing and opioids, also present considerable financial uncertainty. While the company is actively managing its debt and pursuing strategic acquisitions to bolster its innovative pipeline, the immediate financial performance is weak. A 'hold' recommendation is appropriate as the company navigates these challenges and executes its strategic transformation. Investors should monitor the resolution of the Indore facility issues, the progress of new product development, and the outcomes of major litigations before considering a stronger position.

Keywords

Pharmaceuticals, Generics, Branded Drugs, SEC Filing, 10-Q, Financial Results, Goodwill Impairment, FDA Warning Letter, Indore Facility, Drug Pricing Litigation, Opioid Litigation, Share Repurchase, Acquisitions, R&D, Viatris